McKesson Corporation (MCK): Price and Financial Metrics
McKesson Corporation (MCK)
Today's Latest Price: $153.04 USD
Updated Oct 20 4:03pm
Add MCK to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 70 in Medical - Services
See all "A" rated Strong Buy stocks
MCK Stock Summary
- Mckesson Corp's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 99.32% of US listed stocks.
- MCK's price/sales ratio is 0.11; that's higher than the P/S ratio of only 3.22% of US stocks.
- The volatility of Mckesson Corp's share price is greater than that of only 2.35% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to MCK, based on their financial statements, market capitalization, and price volatility, are SYY, ABC, MAT, BGI, and DXLG.
- MCK's SEC filings can be seen here. And to visit Mckesson Corp's official web site, go to www.mckesson.com.
MCK Stock Price Chart Interactive Chart >
MCK Price/Volume Stats
| Current price | $153.04 | 52-week high | $172.18 |
| Prev. close | $152.42 | 52-week low | $112.60 |
| Day low | $152.57 | Volume | 786,943 |
| Day high | $155.40 | Avg. volume | 2,497,040 |
| 50-day MA | $151.52 | Dividend yield | 1.1% |
| 200-day MA | $148.01 | Market Cap | 24.82B |
McKesson Corporation (MCK) Company Bio
Mckesson Corporation partners with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. The company was founded in 1833 and is based in San Francisco, California.
MCK Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $153.04 | $139.01 | -9% |
Below please find a table outlining a discounted cash flow forecast for MCK, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Mckesson Corp ranked in the 44th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for MCK, they are:
- Its compound free cash flow growth rate, as measured over the past 5.5 years, is -0.03% -- higher than just 21.21% of stocks in our DCF forecasting set.
- The company has produced more trailing twelve month cash flow than 88.96% of its sector Healthcare.
- Mckesson Corp's weighted average cost of capital (WACC) is 7%; for context, that number is higher than merely 13.47% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -11% |
| 1% | -10% |
| 2% | -9% |
| 3% | -8% |
| 4% | -7% |
| 5% | -6% |
Want more companies with a valuation profile/forecast similar to that of Mckesson Corp? See MEDP, DXCM, AMED, HBIO, and USPH.
Loading social stream, please wait...